Clinical trial
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab…
NCT02662985 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT02662985 |
|---|---|
| Title | Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) |
| Official title | A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis |
| Acronym | PDUS |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriatic Arthritis |
| Intervention type | Drug |
| Interventions | AIN457 (secukinumab), Placebo |
| Enrollment | 166 |
| Start date | Aug 22, 2016 |
| Primary completion | Nov 10, 2020 |
| Completion | Nov 10, 2020 |
| First posted | Jan 26, 2016 |
| Last update posted | Dec 7, 2021 |
| Countries | Argentina, Austria, Belgium, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: